个人中心 - 老虎社区

MuffinsDaddy

IP属地：未知

帖子 · 67帖子 · 67
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- MuffinsDaddyMuffinsDaddy
  ·2021-12-31
  K
  The Ride Could Get Bumpy For Lucid Motors Stock
  The fate of LCID stock in 2022 hinges on whether investor sentiment holds for EVs
  The Ride Could Get Bumpy For Lucid Motors Stock
  1,346 1
  1
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-31
  Great ariticle, would you like to share it?
  U.S. Stock Futures Point to Calm Finish to Year of Big Gains
  U.S. stock futures were muted on the last trading day of the year, indicating a quiet finish in a ye
  U.S. Stock Futures Point to Calm Finish to Year of Big Gains
  1,331 1
  4
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-29
  L
  Toplines Before US Market Open on Wednesday
  U.S. stock index futures rose on Wednesday, as heavyweight Tesla gained, while hopes that the Omicro
  Toplines Before US Market Open on Wednesday
  1,416 1
  4
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-28
  K
  Tesla Analyst Says 2022 Could Be An Inflection Point For EV Maker; Sees Capacity Double By End Of Year
  Tesla Inc is heading into an inflection point next year as it looks to double production capacity to
  Tesla Analyst Says 2022 Could Be An Inflection Point For EV Maker; Sees Capacity Double By End Of Year
  1,512 1
  1
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-27
  K
  10 Biggest Price Target Changes For Monday
  Morgan Stanley cut Foot Locker, Inc. (NYSE:FL) price target from $66 to $47. Foot Locker shares fell
  10 Biggest Price Target Changes For Monday
  987 1
  3
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-26
  K
  非常抱歉，此主贴已删除
  1,402 1
  3
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-25
  K
  非常抱歉，此主贴已删除
  1,029 3
  3
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-24
  K
  非常抱歉，此主贴已删除
  1,143 2
  4
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-23
  K
  非常抱歉，此主贴已删除
  1,062 1
  1
  分享
  举报
- MuffinsDaddyMuffinsDaddy
  ·2021-12-22
  O
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
  Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data
  1,312 1
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3584049778248855","uuid":"3584049778248855","gmtCreate":1620958334504,"gmtModify":1620985800195,"name":"MuffinsDaddy","pinyin":"muffinsdaddy","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":38,"headSize":394,"tweetSize":67,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-2","templateUuid":"35ec162348d5460f88c959321e554969","name":"宗师交易员","description":"证券或期货账户累计交易次数达到100次","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.51%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":692629785,"gmtCreate":1640946870321,"gmtModify":1640946870737,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692629785","repostId":"1161129852","repostType":4,"repost":{"id":"1161129852","kind":"news","pubTimestamp":1640936405,"share":"https://www.laohunote.com/m/news/1161129852?lang=&edition=full","pubTime":"2021-12-31 15:40","market":"us","language":"en","title":"The Ride Could Get Bumpy For Lucid Motors Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1161129852","media":"InvestorPlace","summary":"The fate of LCID stock in 2022 hinges on whether investor sentiment holds for EVs","content":"<html><head></head><body><p>It’s an understatement to say <b>Lucid Group</b> (NASDAQ:<b><u>LCID</u></b>) and LCID stock had a very good 2021. But will this be the case for 2022? It depends on two things happening.</p><p>First, the EV maker will need to continue making progress at the same pace it’s been doing so lately. Second, and more importantly, its performance in 2022 hinges heavily on investor sentiment for vehicle electrification plays.</p><p>The first factor appears likely to pan out, even if it’s unclear whether Lucid can commence mass production without facing too many hiccups and hurdles. However, the jury’s still out on the second factor.</p><p>Based on how EV stocks are stabilizing, it may seem a bit alarmist to believe more deflation of the EV bubble is set to happen. Yet if the market conditions that created this bubble in the first continue to change, another round of big declines may lie ahead for Lucid, along with the higher prominent electric vehicle names like <b>Tesla</b>(NASDAQ:<b><u>TSLA</u></b>) and <b>Rivian</b>(NASDAQ:<b><u>RIVN</u></b>).</p><p>If you’re bullish on the EV megatrend, you may believe LCID stock is a winner that will keep on winning. But it’s important to keep in mind how changing sentiment could affect its performance.</p><p><b>The Latest With LCID Stock</b></p><p>Settling down after its late November/early December slide, Lucid is finishing up the year quietly. Two more positive developments ($1.75 billion convertible debt offering,inclusion in the <b>NASDAQ-100</b> index) helped to counter more negative news, such as its disclosure of a Securities and Exchange Commission subpoena about the special purpose acquisition company (SPAC) deal that took it public earlier this year.</p><p>With this, plus the market calming down with its omicron/Fed worries, LCID stock has found support. As of this writing, it’s trading between $35 and $40 per share. But while the stock was a big winner in 2021 (up 280%), this may not be the case in 2022.</p><p>Again, concerns are not so much due to the risk that it drops the ball in the next 12 months. Based on how successful its execution has been this year, it’s hard to doubt that Lucid will meet its production goals for the next two years (20,000 vehicles in 2022, 50,000 vehicles in 2023).</p><p>Yet if in the months ahead, bullishness for EV plays continues to cool down? Meeting and/or beating near-term expectations may not be enough for it to hold onto its rich valuation.</p><p><b>Rising Rates Could Still Keep Lucid in Reverse</b></p><p>The market’s appetite for growth stocks played a big role in sending LCID stock to the moon this year. However, based on how sentiment is shifting, this may not continue in the months ahead.</p><p>That is, market environment is more likely to become more unfavorable to growth stocks. As the Federal Reserve continues to take on a more hawkish tone, mentioning faster tapering and rate hikes for 2022, growth stocks are going to continue to lose their luster.</p><p>In turn,the pivot away from riskier assets like early-stage growth stocks will carry on. Firmly in that category, EV stocks like Lucid will likely face more downward pressure. This could far outweigh company-specific positives, such as the budding automaker successfully ramping up production, or wowing Wall Street with its delivery numbers.</p><p>To what extent could that affect LCID stock over the next 12 months? At this point, it’s hard to tell.  We could see EV stocks experience an extended sell-off, much like what happened with internet stocks following the bursting of the dot-com bubble. As you may recall, even the dot-com winners in the making, like <b>Amazon</b>(NASDAQ:<b><u>AMZN</u></b>), saw massive drawdowns and took many years to get back to their respective high-water marks.</p><p><b>The Bottom Line</b></p><p>Based upon its success this year, it’s easy to be confident things will continue to work out favorably for Lucid. Yet whether that happens to LCID stock as well remains to be seen. The winds are blowing differently today than they were as recently as late November.</p><p>A return to normal for Fed monetary policy may signal the end of the epic run growth stocks have gone on since the start of the coronavirus pandemic. As the market’s view on EV stocks is in the driver’s seat, what’s the takeaway?</p><p>Before buying LCID stock just on your bullishness for the EV trend, take a read of the room. If it appears the cycling out of growth stocks will continue, it’s best to wait before buying it.</p></body></html>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Ride Could Get Bumpy For Lucid Motors Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Ride Could Get Bumpy For Lucid Motors Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-31 15:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/12/lcid-stock-ride-could-get-bumpy/><strong>InvestorPlace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>It’s an understatement to say Lucid Group (NASDAQ:LCID) and LCID stock had a very good 2021. But will this be the case for 2022? It depends on two things happening.First, the EV maker will need to ...</p>\n\n<a href=\"https://investorplace.com/2021/12/lcid-stock-ride-could-get-bumpy/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"LCID":"Lucid Group Inc"},"source_url":"https://investorplace.com/2021/12/lcid-stock-ride-could-get-bumpy/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1161129852","content_text":"It’s an understatement to say Lucid Group (NASDAQ:LCID) and LCID stock had a very good 2021. But will this be the case for 2022? It depends on two things happening.First, the EV maker will need to continue making progress at the same pace it’s been doing so lately. Second, and more importantly, its performance in 2022 hinges heavily on investor sentiment for vehicle electrification plays.The first factor appears likely to pan out, even if it’s unclear whether Lucid can commence mass production without facing too many hiccups and hurdles. However, the jury’s still out on the second factor.Based on how EV stocks are stabilizing, it may seem a bit alarmist to believe more deflation of the EV bubble is set to happen. Yet if the market conditions that created this bubble in the first continue to change, another round of big declines may lie ahead for Lucid, along with the higher prominent electric vehicle names like Tesla(NASDAQ:TSLA) and Rivian(NASDAQ:RIVN).If you’re bullish on the EV megatrend, you may believe LCID stock is a winner that will keep on winning. But it’s important to keep in mind how changing sentiment could affect its performance.The Latest With LCID StockSettling down after its late November/early December slide, Lucid is finishing up the year quietly. Two more positive developments ($1.75 billion convertible debt offering,inclusion in the NASDAQ-100 index) helped to counter more negative news, such as its disclosure of a Securities and Exchange Commission subpoena about the special purpose acquisition company (SPAC) deal that took it public earlier this year.With this, plus the market calming down with its omicron/Fed worries, LCID stock has found support. As of this writing, it’s trading between $35 and $40 per share. But while the stock was a big winner in 2021 (up 280%), this may not be the case in 2022.Again, concerns are not so much due to the risk that it drops the ball in the next 12 months. Based on how successful its execution has been this year, it’s hard to doubt that Lucid will meet its production goals for the next two years (20,000 vehicles in 2022, 50,000 vehicles in 2023).Yet if in the months ahead, bullishness for EV plays continues to cool down? Meeting and/or beating near-term expectations may not be enough for it to hold onto its rich valuation.Rising Rates Could Still Keep Lucid in ReverseThe market’s appetite for growth stocks played a big role in sending LCID stock to the moon this year. However, based on how sentiment is shifting, this may not continue in the months ahead.That is, market environment is more likely to become more unfavorable to growth stocks. As the Federal Reserve continues to take on a more hawkish tone, mentioning faster tapering and rate hikes for 2022, growth stocks are going to continue to lose their luster.In turn,the pivot away from riskier assets like early-stage growth stocks will carry on. Firmly in that category, EV stocks like Lucid will likely face more downward pressure. This could far outweigh company-specific positives, such as the budding automaker successfully ramping up production, or wowing Wall Street with its delivery numbers.To what extent could that affect LCID stock over the next 12 months? At this point, it’s hard to tell.  We could see EV stocks experience an extended sell-off, much like what happened with internet stocks following the bursting of the dot-com bubble. As you may recall, even the dot-com winners in the making, like Amazon(NASDAQ:AMZN), saw massive drawdowns and took many years to get back to their respective high-water marks.The Bottom LineBased upon its success this year, it’s easy to be confident things will continue to work out favorably for Lucid. Yet whether that happens to LCID stock as well remains to be seen. The winds are blowing differently today than they were as recently as late November.A return to normal for Fed monetary policy may signal the end of the epic run growth stocks have gone on since the start of the coronavirus pandemic. As the market’s view on EV stocks is in the driver’s seat, what’s the takeaway?Before buying LCID stock just on your bullishness for the EV trend, take a read of the room. If it appears the cycling out of growth stocks will continue, it’s best to wait before buying it.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1346,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692629544,"gmtCreate":1640946790015,"gmtModify":1640946790405,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692629544","repostId":"1122161745","repostType":4,"repost":{"id":"1122161745","kind":"news","pubTimestamp":1640945508,"share":"https://www.laohunote.com/m/news/1122161745?lang=&edition=full","pubTime":"2021-12-31 18:11","market":"us","language":"en","title":"U.S. Stock Futures Point to Calm Finish to Year of Big Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=1122161745","media":"Wall Street Journal","summary":"U.S. stock futures were muted on the last trading day of the year, indicating a quiet finish in a ye","content":"<html><head></head><body><p>U.S. stock futures were muted on the last trading day of the year, indicating a quiet finish in a year of repeated records on Wall Street on low interest rates and the rollout of Covid-19 vaccines.</p><p>Futures for the S&amp;P 500 edged down less than 0.1% Friday. The broad-market index finished slightly lower Thursday but is on course to finish the year about 27% higher, which would be its largest annual percentage gain since 2019. Contracts for the tech-focused Nasdaq-100 and futures for the Dow Jones Industrial Average each ticked almost 0.1% lower Friday.</p><p>The calm trading Friday juxtaposes a busy year in markets in which individual investors piled into meme stocks and the rollout of Covid-19 vaccines and low interest rates incentivized investments in equities. These factors helped lead the S&amp;P 500 to close at a record 70 times this year, more than a quarter of all trading days, according to Dow Jones Market Data.</p><p>Much of the broader market rally was also driven by a small group of massive stocks, such as Apple,Tesla and Microsoft.Microsoft and Tesla shares have each risen more than 50% this year, while Apple has gained more than 30%.</p><p>“This is really the year of the economic recovery,” said Sean Markowicz, an investment strategist at Schroders. “In 2022, I see growth cooling as the massive policy stimulus in response to the pandemic fades.”</p><p>Investors are watching a number of risks heading into 2022 that could derail the market’s rally. Cases of the Omicron variant of Covid-19 are surging, causing some businesses to curtail services and hours as workers call in sick. U.S. inflation reached a nearly four-decade high last month, raising questions about how many price increases Americans can absorb and if that will affect corporate earnings. The Federal Reserve has also set the stage for a series of interest-rate increases beginning next spring.</p><p>In bond markets, the yield on the benchmark 10-year Treasury note was unchanged from 1.514% Thursday. The yield rose 0.601 percentage points this year as of Thursday, the largest one-year yield gain since 2013, according to Dow Jones Market Data. Investors have sold out of government bonds, pushing up yields, because holding bonds that yield less than inflation means locking in a loss. Yields and prices move inversely.</p><p>Overseas, the pan-continental Stoxx Europe 600 was flat, with markets closed in Germany, Spain and Italy. The broad-market index has risen more than 20% this year.</p><p>Shares of Chinese internet and technology companies jumped in Hong Kong on the last day of the year, following a surge in their corresponding American depositary receipts overnight. The Hang Seng Tech Index, which tracks the 30 largest technology companies listed in the city, rose 3.6% on Friday in a holiday-shortened trading session. The broader Hang Seng Index gained 1.2%.</p><p>China’s Shanghai Composite added 0.6% Friday. Markets in South Korea and Japan were closed for a holiday.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>U.S. Stock Futures Point to Calm Finish to Year of Big Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nU.S. Stock Futures Point to Calm Finish to Year of Big Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-31 18:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/global-stock-markets-dow-update-12-31-2021-11640940181?mod=markets_lead_pos1><strong>Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>U.S. stock futures were muted on the last trading day of the year, indicating a quiet finish in a year of repeated records on Wall Street on low interest rates and the rollout of Covid-19 vaccines....</p>\n\n<a href=\"https://www.wsj.com/articles/global-stock-markets-dow-update-12-31-2021-11640940181?mod=markets_lead_pos1\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite",".DJI":"道琼斯"},"source_url":"https://www.wsj.com/articles/global-stock-markets-dow-update-12-31-2021-11640940181?mod=markets_lead_pos1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1122161745","content_text":"U.S. stock futures were muted on the last trading day of the year, indicating a quiet finish in a year of repeated records on Wall Street on low interest rates and the rollout of Covid-19 vaccines.Futures for the S&P 500 edged down less than 0.1% Friday. The broad-market index finished slightly lower Thursday but is on course to finish the year about 27% higher, which would be its largest annual percentage gain since 2019. Contracts for the tech-focused Nasdaq-100 and futures for the Dow Jones Industrial Average each ticked almost 0.1% lower Friday.The calm trading Friday juxtaposes a busy year in markets in which individual investors piled into meme stocks and the rollout of Covid-19 vaccines and low interest rates incentivized investments in equities. These factors helped lead the S&P 500 to close at a record 70 times this year, more than a quarter of all trading days, according to Dow Jones Market Data.Much of the broader market rally was also driven by a small group of massive stocks, such as Apple,Tesla and Microsoft.Microsoft and Tesla shares have each risen more than 50% this year, while Apple has gained more than 30%.“This is really the year of the economic recovery,” said Sean Markowicz, an investment strategist at Schroders. “In 2022, I see growth cooling as the massive policy stimulus in response to the pandemic fades.”Investors are watching a number of risks heading into 2022 that could derail the market’s rally. Cases of the Omicron variant of Covid-19 are surging, causing some businesses to curtail services and hours as workers call in sick. U.S. inflation reached a nearly four-decade high last month, raising questions about how many price increases Americans can absorb and if that will affect corporate earnings. The Federal Reserve has also set the stage for a series of interest-rate increases beginning next spring.In bond markets, the yield on the benchmark 10-year Treasury note was unchanged from 1.514% Thursday. The yield rose 0.601 percentage points this year as of Thursday, the largest one-year yield gain since 2013, according to Dow Jones Market Data. Investors have sold out of government bonds, pushing up yields, because holding bonds that yield less than inflation means locking in a loss. Yields and prices move inversely.Overseas, the pan-continental Stoxx Europe 600 was flat, with markets closed in Germany, Spain and Italy. The broad-market index has risen more than 20% this year.Shares of Chinese internet and technology companies jumped in Hong Kong on the last day of the year, following a surge in their corresponding American depositary receipts overnight. The Hang Seng Tech Index, which tracks the 30 largest technology companies listed in the city, rose 3.6% on Friday in a holiday-shortened trading session. The broader Hang Seng Index gained 1.2%.China’s Shanghai Composite added 0.6% Friday. Markets in South Korea and Japan were closed for a holiday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1331,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692007700,"gmtCreate":1640787101032,"gmtModify":1640787101521,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"L","listText":"L","text":"L","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/692007700","repostId":"1105117108","repostType":4,"repost":{"id":"1105117108","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640782444,"share":"https://www.laohunote.com/m/news/1105117108?lang=&edition=full","pubTime":"2021-12-29 20:54","market":"us","language":"en","title":"Toplines Before US Market Open on Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=1105117108","media":"Tiger Newspress","summary":"U.S. stock index futures rose on Wednesday, as heavyweight Tesla gained, while hopes that the Omicro","content":"<html><head></head><body><p>U.S. stock index futures rose on Wednesday, as heavyweight Tesla gained, while hopes that the Omicron coronavirus variant is less deadly than the previous strain calmed investors amid daily cases in the country hitting a record high.</p><p>At 7:43 a.m. ET, Dow e-minis were up 3 points, or 0.06%, S&amp;P 500 e-minis were up 3 points, or 0.01%, and Nasdaq 100 e-minis were up 29.25 points, or 0.18%.</p><p><img src=\"https://static.tigerbbs.com/7ceef07d87ec8d52d1c5d44cfe0e4400\" tg-width=\"1080\" tg-height=\"409\" referrerpolicy=\"no-referrer\"/></p><p><b>Stocks making the biggest moves premarket:</b></p><p><b>FuelCell Energy(FCEL)</b> – The fuel cell technology company lost 7 cents per share for its latest quarter, wider than the 4-cent loss predicted by analysts. Revenue also fell below analyst forecasts, and the stock slumped 9% in premarket trading.</p><p><b>BioNTech(BNTX) </b>– The drug maker&#39;s shares fell 3.1% in the premarket, potentially extending the stock&#39;s losing streak to 7 days. BioNTech has fallen 16% over the past 6 sessions. Rival vaccine maker <b>Moderna(MRNA)</b> is in a similar slump, falling for the past six sessions and falling 18% over that stretch. Moderna dropped 1.6% in premarket action.</p><p><b>Tesla(TSLA)</b> – Tesla rose 1% in premarket trading, following news that CEO Elon Musk completed the exercising of all his stock options for next year. That signals the end of recent stock sales by Musk to cover tax bills generated by the exercise of those options.</p><p><b>Rivian(RIVN)</b> – Rivian dropped 2.2% in premarket trading,following the company reportedly made a decision to delay the bigger battery pack for its electric pickup all the way to 2023.</p><p><b>Cal-Maine Foods(CALM)</b> – The nation&#39;s largest egg producer earned 2 cents per share for its latest quarter, well short of the 30-cent consensus estimate. Sales were better-than-expected, but the bottom line was hit by higher costs for packaging and labor. Cal-Maine shares tumbled 7.1% in the premarket.</p><p><b>Alibaba(BABA)</b> – The China-based e-commerce giant is considering the sale of its 30% stake in social media advertising company <b>Weibo(WB)</b> to state-owned Shanghai Media Group, according to a Bloomberg report. Alibaba fell 1% in premarket action, while Weibo edged lower by 0.3%.</p><p><b>Didi Global(DIDI) </b>– Didi was down 2.4% in premarket trading after Reuters reported the Chinese ride-hailing company will use the “listing by introduction” method to list in Hong Kong, as it moves to delist in New York. That method would issue no new shares and raise no capital.</p><p><b>Victoria’s Secret(VSCO)</b> – The intimate apparel retailer announced a $250 million accelerated share repurchase program.Its shares jumped 9% in premarket trading.</p><p><b>Akamai Technologies(AKAM)</b> – Akamai rose 1.2% in the premarket after D.A. Davidson rated the internet content delivery company a “buy” in new coverage. The firm set a price target of $143 per share, compared with Tuesday’s close of $118.45.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Toplines Before US Market Open on Wednesday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nToplines Before US Market Open on Wednesday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-29 20:54</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>U.S. stock index futures rose on Wednesday, as heavyweight Tesla gained, while hopes that the Omicron coronavirus variant is less deadly than the previous strain calmed investors amid daily cases in the country hitting a record high.</p><p>At 7:43 a.m. ET, Dow e-minis were up 3 points, or 0.06%, S&amp;P 500 e-minis were up 3 points, or 0.01%, and Nasdaq 100 e-minis were up 29.25 points, or 0.18%.</p><p><img src=\"https://static.tigerbbs.com/7ceef07d87ec8d52d1c5d44cfe0e4400\" tg-width=\"1080\" tg-height=\"409\" referrerpolicy=\"no-referrer\"/></p><p><b>Stocks making the biggest moves premarket:</b></p><p><b>FuelCell Energy(FCEL)</b> – The fuel cell technology company lost 7 cents per share for its latest quarter, wider than the 4-cent loss predicted by analysts. Revenue also fell below analyst forecasts, and the stock slumped 9% in premarket trading.</p><p><b>BioNTech(BNTX) </b>– The drug maker&#39;s shares fell 3.1% in the premarket, potentially extending the stock&#39;s losing streak to 7 days. BioNTech has fallen 16% over the past 6 sessions. Rival vaccine maker <b>Moderna(MRNA)</b> is in a similar slump, falling for the past six sessions and falling 18% over that stretch. Moderna dropped 1.6% in premarket action.</p><p><b>Tesla(TSLA)</b> – Tesla rose 1% in premarket trading, following news that CEO Elon Musk completed the exercising of all his stock options for next year. That signals the end of recent stock sales by Musk to cover tax bills generated by the exercise of those options.</p><p><b>Rivian(RIVN)</b> – Rivian dropped 2.2% in premarket trading,following the company reportedly made a decision to delay the bigger battery pack for its electric pickup all the way to 2023.</p><p><b>Cal-Maine Foods(CALM)</b> – The nation&#39;s largest egg producer earned 2 cents per share for its latest quarter, well short of the 30-cent consensus estimate. Sales were better-than-expected, but the bottom line was hit by higher costs for packaging and labor. Cal-Maine shares tumbled 7.1% in the premarket.</p><p><b>Alibaba(BABA)</b> – The China-based e-commerce giant is considering the sale of its 30% stake in social media advertising company <b>Weibo(WB)</b> to state-owned Shanghai Media Group, according to a Bloomberg report. Alibaba fell 1% in premarket action, while Weibo edged lower by 0.3%.</p><p><b>Didi Global(DIDI) </b>– Didi was down 2.4% in premarket trading after Reuters reported the Chinese ride-hailing company will use the “listing by introduction” method to list in Hong Kong, as it moves to delist in New York. That method would issue no new shares and raise no capital.</p><p><b>Victoria’s Secret(VSCO)</b> – The intimate apparel retailer announced a $250 million accelerated share repurchase program.Its shares jumped 9% in premarket trading.</p><p><b>Akamai Technologies(AKAM)</b> – Akamai rose 1.2% in the premarket after D.A. Davidson rated the internet content delivery company a “buy” in new coverage. The firm set a price target of $143 per share, compared with Tuesday’s close of $118.45.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FCEL":"燃料电池能源","BNTX":"BioNTech SE","AKAM":"阿克迈","CALM":"Cal-Maine Foods",".DJI":"道琼斯","BABA":"阿里巴巴","DIDI":"滴滴(已退市)",".IXIC":"NASDAQ Composite","VSCO":"维多利亚的秘密",".SPX":"S&P 500 Index","RIVN":"Rivian Automotive, Inc.","MRNA":"Moderna, Inc.","WB":"微博","TSLA":"特斯拉"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105117108","content_text":"U.S. stock index futures rose on Wednesday, as heavyweight Tesla gained, while hopes that the Omicron coronavirus variant is less deadly than the previous strain calmed investors amid daily cases in the country hitting a record high.At 7:43 a.m. ET, Dow e-minis were up 3 points, or 0.06%, S&P 500 e-minis were up 3 points, or 0.01%, and Nasdaq 100 e-minis were up 29.25 points, or 0.18%.Stocks making the biggest moves premarket:FuelCell Energy(FCEL) – The fuel cell technology company lost 7 cents per share for its latest quarter, wider than the 4-cent loss predicted by analysts. Revenue also fell below analyst forecasts, and the stock slumped 9% in premarket trading.BioNTech(BNTX) – The drug maker's shares fell 3.1% in the premarket, potentially extending the stock's losing streak to 7 days. BioNTech has fallen 16% over the past 6 sessions. Rival vaccine maker Moderna(MRNA) is in a similar slump, falling for the past six sessions and falling 18% over that stretch. Moderna dropped 1.6% in premarket action.Tesla(TSLA) – Tesla rose 1% in premarket trading, following news that CEO Elon Musk completed the exercising of all his stock options for next year. That signals the end of recent stock sales by Musk to cover tax bills generated by the exercise of those options.Rivian(RIVN) – Rivian dropped 2.2% in premarket trading,following the company reportedly made a decision to delay the bigger battery pack for its electric pickup all the way to 2023.Cal-Maine Foods(CALM) – The nation's largest egg producer earned 2 cents per share for its latest quarter, well short of the 30-cent consensus estimate. Sales were better-than-expected, but the bottom line was hit by higher costs for packaging and labor. Cal-Maine shares tumbled 7.1% in the premarket.Alibaba(BABA) – The China-based e-commerce giant is considering the sale of its 30% stake in social media advertising company Weibo(WB) to state-owned Shanghai Media Group, according to a Bloomberg report. Alibaba fell 1% in premarket action, while Weibo edged lower by 0.3%.Didi Global(DIDI) – Didi was down 2.4% in premarket trading after Reuters reported the Chinese ride-hailing company will use the “listing by introduction” method to list in Hong Kong, as it moves to delist in New York. That method would issue no new shares and raise no capital.Victoria’s Secret(VSCO) – The intimate apparel retailer announced a $250 million accelerated share repurchase program.Its shares jumped 9% in premarket trading.Akamai Technologies(AKAM) – Akamai rose 1.2% in the premarket after D.A. Davidson rated the internet content delivery company a “buy” in new coverage. The firm set a price target of $143 per share, compared with Tuesday’s close of $118.45.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1416,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696283872,"gmtCreate":1640702693634,"gmtModify":1640702694079,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696283872","repostId":"1158199502","repostType":4,"repost":{"id":"1158199502","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640684313,"share":"https://www.laohunote.com/m/news/1158199502?lang=&edition=full","pubTime":"2021-12-28 17:38","market":"us","language":"en","title":"Tesla Analyst Says 2022 Could Be An Inflection Point For EV Maker; Sees Capacity Double By End Of Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1158199502","media":"Benzinga","summary":"Tesla Inc is heading into an inflection point next year as it looks to double production capacity to","content":"<p><b>Tesla Inc</b>&nbsp;is heading into an inflection point next year as it looks to double production capacity to about 2 million units annually with the opening of two new Giga factories by the end of 2022.</p>\n<p><img src=\"https://static.tigerbbs.com/1a282389d9f75c888402719fc93d2598\" tg-width=\"1200\" tg-height=\"630\" width=\"100%\" height=\"auto\"></p>\n<p><b>The Tesla Analyst: Wedbush</b>&nbsp;analyst Daniel Ives has maintained an Outperform rating and a price target of $1,400 a share on the Tesla stock.</p>\n<p><b>The Tesla Thesis:</b>&nbsp;A Tesla bull, Ives, said the&nbsp;<b>Elon</b>&nbsp;<b>Musk</b>-led electric vehicle company has navigated the ongoing chip supply shortages better than all other automakers in the past six months and is well-positioned to leverage that in 2022.</p>\n<p>Ives pointed out that the Austin, Texas-based headquarter will further benefit with higher capacity when two of its Giga factories double capacity to nearly 2 million vehicles annually.</p>\n<p>In Berlin, Tesla’s Gigafactory is expected to&nbsp;secure the start of production approval&nbsp;in early 2022. The electric vehicle maker is expected to wrap up construction at Giga Texas by Dec. 31.</p>\n<p>“Right now Tesla has a high-class problem of demand outstripping supply with this issue now translating into ~5-6 month delays for Model Ys, some Model 3s in different parts of the globe,” Ives wrote in a note.</p>\n<p>“The key to alleviating these issues is centered around the key Giga openings in Austin and Berlin which will alleviate the bottlenecks of production for Tesla globally.”</p>\n<p>Ives has estimated Tesla still has some red-tape bureaucratic issues to resolve in Berlin before it begins production in the “January/February timeframe.”</p>\n<p>The brokerage&nbsp;has previously estimated EVs will globally represent 10% of autos by 2025&nbsp;and 30% by 2030. According to Ives, China could represent 40% of Tesla’s deliveries next year, or worth $400 per share in 2022.”</p>\n<p><b>Why It Matters:</b>&nbsp;Tesla delivered record third-quarter sales but said it was struggling with chip supplies, forcing its Musk to say the electric vehicle maker does not have a demand problem, but it faces a production ramp-up issue.</p>\n<p>Legacy rivals such as&nbsp;<b>Ford Motor Co</b>&nbsp;<b>General Motors Co</b>&nbsp;were forced to halt production this year at various U.S. factories due to the chip crisis.</p>\n<p><b>TSLA Price Action:</b>Tesla shares gained 2.5% Monday, closing at $1,093.94 a share.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tesla Analyst Says 2022 Could Be An Inflection Point For EV Maker; Sees Capacity Double By End Of Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTesla Analyst Says 2022 Could Be An Inflection Point For EV Maker; Sees Capacity Double By End Of Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-28 17:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Tesla Inc</b>&nbsp;is heading into an inflection point next year as it looks to double production capacity to about 2 million units annually with the opening of two new Giga factories by the end of 2022.</p>\n<p><img src=\"https://static.tigerbbs.com/1a282389d9f75c888402719fc93d2598\" tg-width=\"1200\" tg-height=\"630\" width=\"100%\" height=\"auto\"></p>\n<p><b>The Tesla Analyst: Wedbush</b>&nbsp;analyst Daniel Ives has maintained an Outperform rating and a price target of $1,400 a share on the Tesla stock.</p>\n<p><b>The Tesla Thesis:</b>&nbsp;A Tesla bull, Ives, said the&nbsp;<b>Elon</b>&nbsp;<b>Musk</b>-led electric vehicle company has navigated the ongoing chip supply shortages better than all other automakers in the past six months and is well-positioned to leverage that in 2022.</p>\n<p>Ives pointed out that the Austin, Texas-based headquarter will further benefit with higher capacity when two of its Giga factories double capacity to nearly 2 million vehicles annually.</p>\n<p>In Berlin, Tesla’s Gigafactory is expected to&nbsp;secure the start of production approval&nbsp;in early 2022. The electric vehicle maker is expected to wrap up construction at Giga Texas by Dec. 31.</p>\n<p>“Right now Tesla has a high-class problem of demand outstripping supply with this issue now translating into ~5-6 month delays for Model Ys, some Model 3s in different parts of the globe,” Ives wrote in a note.</p>\n<p>“The key to alleviating these issues is centered around the key Giga openings in Austin and Berlin which will alleviate the bottlenecks of production for Tesla globally.”</p>\n<p>Ives has estimated Tesla still has some red-tape bureaucratic issues to resolve in Berlin before it begins production in the “January/February timeframe.”</p>\n<p>The brokerage&nbsp;has previously estimated EVs will globally represent 10% of autos by 2025&nbsp;and 30% by 2030. According to Ives, China could represent 40% of Tesla’s deliveries next year, or worth $400 per share in 2022.”</p>\n<p><b>Why It Matters:</b>&nbsp;Tesla delivered record third-quarter sales but said it was struggling with chip supplies, forcing its Musk to say the electric vehicle maker does not have a demand problem, but it faces a production ramp-up issue.</p>\n<p>Legacy rivals such as&nbsp;<b>Ford Motor Co</b>&nbsp;<b>General Motors Co</b>&nbsp;were forced to halt production this year at various U.S. factories due to the chip crisis.</p>\n<p><b>TSLA Price Action:</b>Tesla shares gained 2.5% Monday, closing at $1,093.94 a share.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1158199502","content_text":"Tesla Inc is heading into an inflection point next year as it looks to double production capacity to about 2 million units annually with the opening of two new Giga factories by the end of 2022.\n\nThe Tesla Analyst: Wedbush analyst Daniel Ives has maintained an Outperform rating and a price target of $1,400 a share on the Tesla stock.\nThe Tesla Thesis: A Tesla bull, Ives, said the Elon Musk-led electric vehicle company has navigated the ongoing chip supply shortages better than all other automakers in the past six months and is well-positioned to leverage that in 2022.\nIves pointed out that the Austin, Texas-based headquarter will further benefit with higher capacity when two of its Giga factories double capacity to nearly 2 million vehicles annually.\nIn Berlin, Tesla’s Gigafactory is expected to secure the start of production approval in early 2022. The electric vehicle maker is expected to wrap up construction at Giga Texas by Dec. 31.\n“Right now Tesla has a high-class problem of demand outstripping supply with this issue now translating into ~5-6 month delays for Model Ys, some Model 3s in different parts of the globe,” Ives wrote in a note.\n“The key to alleviating these issues is centered around the key Giga openings in Austin and Berlin which will alleviate the bottlenecks of production for Tesla globally.”\nIves has estimated Tesla still has some red-tape bureaucratic issues to resolve in Berlin before it begins production in the “January/February timeframe.”\nThe brokerage has previously estimated EVs will globally represent 10% of autos by 2025 and 30% by 2030. According to Ives, China could represent 40% of Tesla’s deliveries next year, or worth $400 per share in 2022.”\nWhy It Matters: Tesla delivered record third-quarter sales but said it was struggling with chip supplies, forcing its Musk to say the electric vehicle maker does not have a demand problem, but it faces a production ramp-up issue.\nLegacy rivals such as Ford Motor Co General Motors Co were forced to halt production this year at various U.S. factories due to the chip crisis.\nTSLA Price Action:Tesla shares gained 2.5% Monday, closing at $1,093.94 a share.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1512,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":696339619,"gmtCreate":1640615922572,"gmtModify":1640615922992,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/696339619","repostId":"1198457273","repostType":4,"repost":{"id":"1198457273","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640613022,"share":"https://www.laohunote.com/m/news/1198457273?lang=&edition=full","pubTime":"2021-12-27 21:50","market":"us","language":"en","title":"10 Biggest Price Target Changes For Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=1198457273","media":"Benzinga","summary":"Morgan Stanley cut Foot Locker, Inc. (NYSE:FL) price target from $66 to $47. Foot Locker shares fell","content":"<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> cut Foot Locker, Inc. (NYSE:FL) price target from $66 to $47. Foot Locker shares fell 0.1% to $41.90 in pre-market trading.</p>\n<p>Baird lowered <a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> (NYSE:CVNA) price target from $164 to $248. Carvana shares gained 0.9% to $243.00 in pre-market trading.</p>\n<p>Barclays lowered <a href=\"https://laohu8.com/S/INNV\">InnovAge Holding Corp.</a> (NASDAQ:INNV) price target from $22 to $6.5. InnovAge Holding shares fell 5.3% to $5.03 in pre-market trading.</p>\n<p>Truist Securities lowered the price target for Everbridge, Inc. (NASDAQ:EVBG) from $185 to $85. Everbridge shares rose 1.3% to $70.00 in pre-market trading.</p>\n<p>Rosenblatt raised the price target on SMART Global Holdings, Inc. (NASDAQ:SGH) from $75 to $100. SMART Global shares rose 4.7% to $69.87 in pre-market trading.</p>\n<p>B of A Securities lowered the price target on <a href=\"https://laohu8.com/S/WEBR\">Weber Inc.</a> (NYSE:WEBR) from $20 to $17. Weber shares gained 0.8% to $12.09 in pre-market trading.</p>\n<p>Barclays cut the price target on <a href=\"https://laohu8.com/S/OCDX\">Ortho Clinical Diagnostics Holdings plc</a> (NASDAQ:OCDX) from $350 to $300. Ortho Clinical Diagnostics shares rose 6.9% to close at $21.16 on Thursday.</p>\n<p>Morgan Stanley reduced the price target for Victoria's Secret &amp; Co. (NYSE:VSCO) from $69 to $54. Victoria's Secret shares fell 0.2% to $49.00 in pre-market trading.</p>\n<p>Morgan Stanley cut Revolve Group, Inc. (NYSE:RVLV) price target from $72 to $57. Revolve Group shares fell 0.6% to $56.03 in pre-market trading.</p>\n<p>Ascendiant Capital cut GameStop Corp. (NYSE:GME) price target from $24 to $23. GameStop shares rose 0.6% to $152.98 in pre-market trading.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-12-27 21:50</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p><a href=\"https://laohu8.com/S/MSTLW\">Morgan Stanley</a> cut Foot Locker, Inc. (NYSE:FL) price target from $66 to $47. Foot Locker shares fell 0.1% to $41.90 in pre-market trading.</p>\n<p>Baird lowered <a href=\"https://laohu8.com/S/CVNA\">Carvana Co.</a> (NYSE:CVNA) price target from $164 to $248. Carvana shares gained 0.9% to $243.00 in pre-market trading.</p>\n<p>Barclays lowered <a href=\"https://laohu8.com/S/INNV\">InnovAge Holding Corp.</a> (NASDAQ:INNV) price target from $22 to $6.5. InnovAge Holding shares fell 5.3% to $5.03 in pre-market trading.</p>\n<p>Truist Securities lowered the price target for Everbridge, Inc. (NASDAQ:EVBG) from $185 to $85. Everbridge shares rose 1.3% to $70.00 in pre-market trading.</p>\n<p>Rosenblatt raised the price target on SMART Global Holdings, Inc. (NASDAQ:SGH) from $75 to $100. SMART Global shares rose 4.7% to $69.87 in pre-market trading.</p>\n<p>B of A Securities lowered the price target on <a href=\"https://laohu8.com/S/WEBR\">Weber Inc.</a> (NYSE:WEBR) from $20 to $17. Weber shares gained 0.8% to $12.09 in pre-market trading.</p>\n<p>Barclays cut the price target on <a href=\"https://laohu8.com/S/OCDX\">Ortho Clinical Diagnostics Holdings plc</a> (NASDAQ:OCDX) from $350 to $300. Ortho Clinical Diagnostics shares rose 6.9% to close at $21.16 on Thursday.</p>\n<p>Morgan Stanley reduced the price target for Victoria's Secret &amp; Co. (NYSE:VSCO) from $69 to $54. Victoria's Secret shares fell 0.2% to $49.00 in pre-market trading.</p>\n<p>Morgan Stanley cut Revolve Group, Inc. (NYSE:RVLV) price target from $72 to $57. Revolve Group shares fell 0.6% to $56.03 in pre-market trading.</p>\n<p>Ascendiant Capital cut GameStop Corp. (NYSE:GME) price target from $24 to $23. GameStop shares rose 0.6% to $152.98 in pre-market trading.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","BK4504":"桥水持仓","GME":"游戏驿站","RVLV":"Revolve Group, LLC","FL":"富乐客","BK4532":"文艺复兴科技持仓","TGT":"塔吉特","BK4114":"综合货品商店","INNV":"InnovAge Holding Corp.","CVNA":"Carvana Co.","VSCO":"维多利亚的秘密","EVBG":"Everbridge Inc.","WEBR":"Weber Inc.","OCDX":"Ortho Clinical Diagnostics Holdings plc"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1198457273","content_text":"Morgan Stanley cut Foot Locker, Inc. (NYSE:FL) price target from $66 to $47. Foot Locker shares fell 0.1% to $41.90 in pre-market trading.\nBaird lowered Carvana Co. (NYSE:CVNA) price target from $164 to $248. Carvana shares gained 0.9% to $243.00 in pre-market trading.\nBarclays lowered InnovAge Holding Corp. (NASDAQ:INNV) price target from $22 to $6.5. InnovAge Holding shares fell 5.3% to $5.03 in pre-market trading.\nTruist Securities lowered the price target for Everbridge, Inc. (NASDAQ:EVBG) from $185 to $85. Everbridge shares rose 1.3% to $70.00 in pre-market trading.\nRosenblatt raised the price target on SMART Global Holdings, Inc. (NASDAQ:SGH) from $75 to $100. SMART Global shares rose 4.7% to $69.87 in pre-market trading.\nB of A Securities lowered the price target on Weber Inc. (NYSE:WEBR) from $20 to $17. Weber shares gained 0.8% to $12.09 in pre-market trading.\nBarclays cut the price target on Ortho Clinical Diagnostics Holdings plc (NASDAQ:OCDX) from $350 to $300. Ortho Clinical Diagnostics shares rose 6.9% to close at $21.16 on Thursday.\nMorgan Stanley reduced the price target for Victoria's Secret & Co. (NYSE:VSCO) from $69 to $54. Victoria's Secret shares fell 0.2% to $49.00 in pre-market trading.\nMorgan Stanley cut Revolve Group, Inc. (NYSE:RVLV) price target from $72 to $57. Revolve Group shares fell 0.6% to $56.03 in pre-market trading.\nAscendiant Capital cut GameStop Corp. (NYSE:GME) price target from $24 to $23. GameStop shares rose 0.6% to $152.98 in pre-market trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":987,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698795469,"gmtCreate":1640529467976,"gmtModify":1640529468389,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698795469","repostId":"2193781141","repostType":4,"isVote":1,"tweetType":1,"viewCount":1402,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698535812,"gmtCreate":1640442982806,"gmtModify":1640442983214,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/698535812","repostId":"2193917819","repostType":4,"isVote":1,"tweetType":1,"viewCount":1029,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698605716,"gmtCreate":1640357501672,"gmtModify":1640357502171,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/698605716","repostId":"1156159690","repostType":4,"isVote":1,"tweetType":1,"viewCount":1143,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":698991117,"gmtCreate":1640271949697,"gmtModify":1640271950109,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/698991117","repostId":"1190771295","repostType":4,"isVote":1,"tweetType":1,"viewCount":1062,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691666770,"gmtCreate":1640185026998,"gmtModify":1640185027378,"author":{"id":"3584049778248855","authorId":"3584049778248855","name":"MuffinsDaddy","avatar":"https://static.tigerbbs.com/29c014d6833d6890a7e317648b998728","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584049778248855","idStr":"3584049778248855"},"themes":[],"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691666770","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohunote.com/m/news/1163953446?lang=&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-12-22 22:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p>\n<p><img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p>\n<p>The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p>\n<p>In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p>\n<p>On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p>\n<p>Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p>\n<p>William Blair downgraded the stock to Market Perform from Outperform.</p>\n<p>Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p>\n<p>With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p>\n<p>Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p>\n<p>SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p>\n<p>Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p>\n<p>Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p>\n<p>Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p>\n<p>LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALLK":"Allakos Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1312,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}